103 related articles for article (PubMed ID: 2681444)
1. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-alpha 2a.
Itri LM; Sherman MI; Palleroni AV; Evans LM; Tran LL; Campion M; Chizzonite R
J Interferon Res; 1989 Sep; 9 Suppl 1():S9-15. PubMed ID: 2681444
[TBL] [Abstract][Full Text] [Related]
2. Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective.
Spiegel RJ; Jacobs SL; Treuhaft MW
J Interferon Res; 1989 Sep; 9 Suppl 1():S17-24. PubMed ID: 2553829
[TBL] [Abstract][Full Text] [Related]
3. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors.
Oberg K; Alm GV
J Interferon Res; 1989 Sep; 9 Suppl 1():S45-9. PubMed ID: 2809277
[TBL] [Abstract][Full Text] [Related]
4. Low incidence of neutralizing antibody formation to interferon-alpha 2b in human recipients.
Dianzani F; Antonelli G; Amicucci P; Cefaro A; Pintus C
J Interferon Res; 1989 Sep; 9 Suppl 1():S33-6. PubMed ID: 2681442
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser.
Larocca AP; Leung SC; Marcus SG; Colby CB; Borden EC
J Interferon Res; 1989 Sep; 9 Suppl 1():S51-60. PubMed ID: 2809278
[TBL] [Abstract][Full Text] [Related]
6. Detection and incidence of neutralizing antibodies to interferon-alpha-n1.
Weck PK; Leventhal BG; Brand C; Finter NB
J Interferon Res; 1989 Sep; 9 Suppl 1():S37-43. PubMed ID: 2553830
[TBL] [Abstract][Full Text] [Related]
7. Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy.
von Wussow P; Jakschies D; Freund M; Deicher H
J Interferon Res; 1989 Sep; 9 Suppl 1():S25-31. PubMed ID: 2809276
[TBL] [Abstract][Full Text] [Related]
8. Antibodies to interferon-alpha 2 in patients treated with interferon-alpha 2 for hairy cell leukemia.
Bekisz JB; zur Nedden DL; Enterline JC; Zoon KC
J Interferon Res; 1989 Sep; 9 Suppl 1():S1-7. PubMed ID: 2809275
[TBL] [Abstract][Full Text] [Related]
9. [Anti-interferon antibody in chronic hepatitis C].
Arai K; Shindo M; Okuno T
Nihon Rinsho; 1994 Jul; 52(7):1929-34. PubMed ID: 7521441
[TBL] [Abstract][Full Text] [Related]
10. [Development of interferon antibodies during the treatment of skin diseases with low-dose recombinant interferon alpha-2a].
Corbillet V; Celerier P; Lebon P; Litoux P; Dreno B
Ann Med Interne (Paris); 1995; 146(6):399-403. PubMed ID: 8597337
[TBL] [Abstract][Full Text] [Related]
11. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa-2a by intramuscular injection.
Itri LM; Campion M; Dennin RA; Palleroni AV; Gutterman JU; Groopman JE; Trown PW
Cancer; 1987 Feb; 59(3 Suppl):668-74. PubMed ID: 10822468
[TBL] [Abstract][Full Text] [Related]
12. Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (Intron A).
Spiegel RJ; Spicehandler JR; Jacobs SL; Oden EM
Am J Med; 1986 Feb; 80(2):223-8. PubMed ID: 3484902
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations.
Antonelli G; Currenti M; Turriziani O; Dianzani F
J Infect Dis; 1991 Apr; 163(4):882-5. PubMed ID: 1901335
[TBL] [Abstract][Full Text] [Related]
14. The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors.
Oberg K; Alm G
Biotherapy; 1997; 10(1):1-5. PubMed ID: 9261544
[TBL] [Abstract][Full Text] [Related]
15. Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment.
Rönnblom LE; Janson ET; Perers A; Oberg KE; Alm GV
Clin Exp Immunol; 1992 Sep; 89(3):330-5. PubMed ID: 1516252
[TBL] [Abstract][Full Text] [Related]
16. Antibodies in patients with recurrent respiratory papillomatosis treated with lymphoblastoid interferon.
Thurmond LM; Brand CM; Leventhal BG; Finter NB; Johnston JM
J Lab Clin Med; 1991 Sep; 118(3):232-40. PubMed ID: 1919296
[TBL] [Abstract][Full Text] [Related]
17. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies.
Steis RG; Smith JW; Urba WJ; Clark JW; Itri LM; Evans LM; Schoenberger C; Longo DL
N Engl J Med; 1988 Jun; 318(22):1409-13. PubMed ID: 3367950
[TBL] [Abstract][Full Text] [Related]
18. Assays for antibodies to human interferon-alpha: the need for standardization.
Schellekens H; Ryff JC; van der Meide PH
J Interferon Cytokine Res; 1997 Jul; 17 Suppl 1():S5-8. PubMed ID: 9241609
[TBL] [Abstract][Full Text] [Related]
19. Resistance to recombinant alpha interferon therapy in idiopathic mixed cryoglobulinemia: reinduction of remission by natural alpha interferon both in antibody-positive and -negative patients.
Casato M; Antonelli G; Maggi F; Pucillo LP; Di Lullo L; Leoni M; Currenti M; Dianzani F; Bonomo L
J Biol Regul Homeost Agents; 1994; 8(2):56-9. PubMed ID: 7863814
[TBL] [Abstract][Full Text] [Related]
20. Clinical investigation of the immunogenicity of interferon-alpha 2a.
Ryff JC
J Interferon Cytokine Res; 1997 Jul; 17 Suppl 1():S29-33. PubMed ID: 9241613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
